Pancreatic Cancer Resectable
33
11
13
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
3.0%
1 terminated out of 33 trials
80.0%
-6.5% vs benchmark
9%
3 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (33)
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
Construction of a Predictive Model for the Efficacy of Chemoprevention Combined With Targeted Therapy in Pancreatic Cancer
Pancreatic Cancer Detection Consortium
Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID)
Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
Antecolic Versus Retrocolic Gastrojejunostomy During Whipple's Procedure
Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer
Effect of an Enhanced Recovery After Surgery Program on Outcomes After Pancreatoduodenectomy
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer
Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer